(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 December 2010 (09.12.2010)

PCT

(10) International Publication Number
WO 2010/140119 A1

(51) **International Patent Classification**:
A61K 39/09 (2006.01)

(21) **International Application Number**:
PCT/IB2010/052445

(22) **International Filing Date**:
1 June 2010 (01.06.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/217,629	1 June 2009 (01.06.2009)	US
61/254,426	23 October 2009 (23.10.2009)	US
61/314,203	16 March 2010 (16.03.2010)	US
61/318,926	30 March 2010 (30.03.2010)	US

(71) **Applicant** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse, CH-4056 Basel (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **MASIGNANI, Vega** [IT/IT]; Novartis Vaccines & Diagnostics, s.r.l. Via Fiorentina 1, I-53100 Siena (IT). **BAROCCHI, Michele Anne** [IT/IT]; Novartis Vaccines & Diagnostics, s.r.l. Via Fiorentina 1, I-53100 Siena (IT). **MOSCHIONI, Monica** [IT/IT]; Novartis Vaccines & Diagnostics, s.r.l. Via Fiorentina 1, I-53100 Siena (IT). **RUGGIERO, Paolo** [IT/IT]; Novartis Vaccines & Diagnostics, s.r.l. Via Fiorentina 1, I-53100 Siena (IT).

(74) **Agents**: **BULLETT, Rachel Margaret** et al.; Carpmaels & Ransford, One Southampton Row, London WC1B 5HA (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2010/140119 A1

(54) **Title**: COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES

(57) **Abstract**: Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic composition can include at least two different clades of RrgB to improve strain coverage against pilus-containing pneumococci. These multiple clades may be present in the immunogenic composition as separate polypeptides or may be fused as a single polypeptide chain.